



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Minutes

Regular Board Meeting

Wednesday, February 19, 2025
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
1.	Call to Order	03
2.	Invocation & Pledge of Allegiance	03
3.	Quorum Call	03
4.	Call for Additional Agenda Items & Adoption of Agenda	04
5.	Consideration of Draft Minutes from Previous Meeting	04
6.	Report on Action Items	04
7.	Confirmation of Acts	04
8.	Opportunity for Public Comment	04
9.	Special Orders of the Day	05
10.	Committee Reports	
	A. Finance	05
	B. Application Review	05
	C. Reciprocity	05
	D. Violations	05
	E. Impairment	06
	F. Reinstatement	07
	G. Tripartite	07
	H. Regulation Revision	08
	I. Executive	13
11.	Staff Reports	
	A. General Counsel	16
	B. Executive Director	18
12.	New Agenda Items Added During Meeting	19
13.	Announcements	19
14.	Adjourn	19

The Louisiana Board of Pharmacy (the “Board”) convened a regular meeting on **Wednesday, February 19, 2025** at the Louisiana Board of Pharmacy located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

1. Call to Order

Mr. Marty McKay, President, called the meeting to order at 9:00 a.m.

2. Invocation & Pledge of Allegiance

Dr. J. Robert Cloud delivered the invocation and Mr. Don L. Resweber led the group in the Pledge of Allegiance.

3. Quorum Call

Mr. McKay called upon Mr. Richard M. Indovina, Jr., Secretary, to call the roll of members to establish a quorum.

Members Present:

Dr. J. Robert Cloud, PharmD
Dr. David G. Collins, PharmD
Mr. David A. Darce
Ms. Jacqueline L. Hall
Mr. Richard M. Indovina, Jr.
Mr. W. Charles Jones
Mr. Kevin LaGrange
Mr. Richard Mannino
Mr. Marty R. McKay
Ms. Chris B. Melancon
Mr. J. Troy Menard
Mr. Anthony G. Mercante
Mr. Robert A. “Butch” Ray
Mr. Don L. Resweber
Mr. Richard A. “Andy” Soileau
Dr. Raymond J. Strong, PharmD

Members Absent:

Ms. Jennifer E. Dupree

Staff Present:

Mr. M. Joseph Fontenot Jr., Executive Director
Mr. Carlos M. Finalet, III, General Counsel
Mr. Benjamin S. Whaley, Chief Compliance Officer
Ms. Kelley L. Villeneuve, Office Manager
Ms. M. Danielle Hartzog, Administrative Program Specialist

Guests:

Mr. Taylor Chrisman – LA House of Representatives
Ms. Jessica Cunningham - LA House of Representatives
Ms. Lauren Paul – CVS Health

Mr. Austin Peavy – CVS Health
Mr. Malcolm J. Broussard – Hygeia Solutions
Mr. Dale Masten – Genoa Healthcare
Ms. Shelly Dupre – Louisiana Alliance of Retail Pharmacies
Ms. Sarah A. Perkins – Breazeale, Sachse & Wilson

Secretary Indovina certified all 16 members were present, constituting a quorum for the conduct of official business.

4. Call for Additional Agenda Items & Adoption of Agenda

Mr. McKay asked if there were any additional agenda items to be added; none were requested. Without objection, the members adopted the posted agenda dated February 17, 2025. There were no objections to Mr. McKay's request for authority to re-order the agenda should the president determine it appropriate to do so.

5. Consideration of Draft Minutes from Previous Meeting

Mr. McKay reminded the members they had received the draft minutes from the regular Board meeting held on November 20, 2024. With no objections, he waived the reading of the draft minutes. With no requests for amendments or corrections, and with no objection, Mr. McKay declared the minutes were approved as presented.

6. Report on Action Items

Mr. McKay called upon Mr. Fontenot for the report. Mr. Fontenot directed the members to the report in their meeting materials which provided an update on the current status of seven regulatory projects and one legislative proposal. The members had no questions and Mr. Fontenot concluded his report.

7. Confirmation of Acts

Pursuant to Mr. McKay's declaration that the officers, members and committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Ms. Hall moved,

Resolved, that the decisions made and the actions taken by the Board officers, members and committees, and executive director in the general conduct and transactions of Board business since November 20, 2024 are approved, adopted, and ratified by the entire Board.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

8. Opportunity for Public Comment

Mr. McKay reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present; none were offered.

*** *Statement of Purpose***

Mr. McKay reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

9. *Special Orders of the Day*

Mr. McKay acknowledged that there were no special orders.

10. *Committee Reports*

A. *Finance Committee*

Mr. McKay called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee has not met since the November Board meeting and the next meeting is tentatively scheduled for August 19, 2025. During the August meeting, the committee will consider the Board's "*Compiled Financial Statements for Fiscal Year 2024-2025*" and provide a recommendation for consideration.

Mr. Soileau concluded his report by recognizing the other members of the committee – Dr. Collins, Mr. Jones, Ms. Melancon, and Mr. Ray.

B. *Application Review Committee*

Mr. McKay called upon Ms. Melancon for the committee report. Ms. Melancon reported that since the last Board meeting, the Board office has not received any applications which require committee consideration and as a result, the committee has not met.

Ms. Melancon concluded her report by recognizing the other members of the committee – Dr. Collins, Mr. Darce, Mr. Mannino and Mr. Ray.

C. *Reciprocity Committee*

Mr. McKay called upon Mr. Mannino for the committee report. Mr. Mannino reported the staff had evaluated 77 applications for pharmacist licensure by reciprocity since the last Board meeting and none of them contained information that warranted a committee level review. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials. Mr. Mannino then directed the members to the list of new pharmacists licensed by reciprocity in their meeting materials.

Mr. Mannino concluded the report by recognizing the other committee members – Mr. Darce, Mr. LaGrange, Mr. Mercante, Mr. Ray, and Mr. Soileau.

D. *Violations Committee*

Mr. McKay called upon Mr. Indovina for the committee report. Mr. Indovina reported the committee met on December 10-11, 2024 to consider several cases on their agenda. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Mr. Indovina directed the members to copies of those proposals in their meeting materials and then presented the following cases to the members for their

consideration.

Paula Dupre Michot Cannon (PST.018113): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her accountability as pharmacist-in-charge (PIC) of Walgreen Pharmacy #11830 regarding several incidents involving patients receiving the wrong medications, the Board issued a letter of reprimand; and further, assessed a fine of \$500 plus administrative and investigative costs.

Walgreen Louisiana Co, Inc, dba Walgreen Pharmacy No. 15199 (New Orleans, LA) (PHY.002125): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to notify the Board of a change in PIC within 30 days of the prior PIC's departure date, the Board assessed a fine of \$1,000 plus administrative and investigative costs.

Vernance Patrice Collins-Burnett (PST.015203): Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her accountability as PIC of ClinicFast Pharmacy regarding improper record keeping, the Board issued a letter of reprimand; and further, ordered that any future application from the licensee to serve as PIC shall be referred to a committee of the Board for consideration; and further, assessed administrative and investigative costs.

Darvis Keon Harvey (PST.018760): Mr. Indovina moved to approve the proposed voluntary consent agreement. There was one member question and no public comments. The motion was adopted after a unanimous vote in the affirmative. For his role at ClinicFast Pharmacy regarding improper record keeping, the Board placed on his license a prohibition from ownership and a prohibition from holding the PIC position for any Louisiana permitted pharmacy, subject to a term; and further, assessed a fine of \$6,000 plus administrative and investigative costs.

Mr. Indovina concluded the report by advising of the next scheduled committee meeting on March 25-26, 2025 to consider 22 cases. Mr. Indovina then recognized the other committee members – Dr. Cloud, Ms. Dupree, Ms. Hall, and Mr. Mercante for their continuing work on the committee.

E. Impairment Committee

Mr. McKay called upon Ms. Hall for the committee report. Ms. Hall reported the committee met the previous day. Following their interviews and subsequent deliberations, the committee developed one recommendation for the Board's consideration. Ms. Hall then presented the following case:

Matthew John Guarisco (PST.014303): Ms. Hall moved to remove condition #2e regarding the pharmacist-in-charge restriction imposed by Board Order issued February 5, 2020. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted a modification of previous order by removing Article 2-e, regarding the PIC restriction, imposed from his February 5, 2020 Probation Board Order.

Ms. Hall closed her report by recognizing the other committee members - Dr. Collins, Mr. Darce, Mr. Menard, Mr. Resweber and Dr. Strong.

F. Reinstatement Committee

Mr. McKay called upon Dr. Strong for the committee report. Dr. Strong reported the committee met the previous day. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Dr. Strong then presented the following cases:

CPT.001365 – Tracy Gautreaux Lovell: Dr. Strong moved to approve the reinstatement of the lapsed certificate conditioned upon completion of certain requirements identified within the proposed non-disciplinary Board order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the request for reinstatement of the lapsed pharmacy technician certificate, conditioned upon her satisfaction of the following requirements prior to February 19, 2027: (1) acquisition of at least 500 hours of updated practical experience under the authority of a special work permit. (2) Successful completion of either the Pharmacy Technician Certification Exam administered by PTCB or the Exam for the Certification of Pharmacy Technicians administered by National HealthCareer Association

PST.020787 – April Henry Eubanks: Dr. Strong moved to approve the reinstatement of the lapsed pharmacist license. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the request for reinstatement of the lapsed pharmacist license without restriction.

Dr. Strong referred the members to the posted committee meeting agenda for a listing of all interim reinstatement actions by the committee chair and staff.

Dr. Strong then concluded his report by recognizing the other committee members - Ms. Dupree, Mr. Jones, Mr. LaGrange, Mr. Mannino, and Mr. Mercante.

G. Tripartite Committee

Mr. McKay called upon Mr. Resweber for the committee report. Mr. Resweber reported that the committee has not met and there was no report at this time. He reminded the members of the continued effort to arrange future meetings in partnership with Louisiana colleges of pharmacy on their campuses.

Mr. Resweber then recognized the other committee members - Ms. Dupree, Mr. Jones, Mr. LaGrange, Mr. Menard, and Dr. Strong.

H. Regulation Revision Committee

Mr. McKay called upon Dr. Cloud for the committee report. Dr. Cloud reported that the committee last met on February 6, 2025 to consider several items on their agenda and developed recommendations for the Board's consideration.

- Legislative Proposal 2025-B ~ CDS Schedules Update (Draft #1)
Dr. Cloud advised that this is the Board's annual bill to match the federal and state lists of controlled substances. The items in this bill were added to the federal list by the DEA and this proposal will place the same items in the same schedule on the state list. Board staff collaborated with the State Police Crime Lab to identify the substances. Dr. Cloud then moved,

***Resolved**, to approve Legislative Proposal 2025-B ~ CDS Schedules Update (Draft #1), and further, to authorize its filing in the Regular Session of the 2025 Legislature, and further, to authorize the President to approve acceptable amendments as may become necessary during the legislative process.*

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Regulatory Project 2025-03 ~ Pharmacy Technician Certificate Qualifications (Draft #2)
Dr. Cloud reminded members that the "Welcome Home Act", which is Act 253 from the 2024 legislative session, provides for universal occupational license recognition. The Act created a requirement for professional and occupational licensing boards to issue a credential to an applicant based on a current and valid occupational license or certification in another state.

Dr. Cloud further explained, during our last Board meeting, members approved Draft #1 of this regulatory project for promulgation. Draft #1 removed the practice requirement of a pharmacy technician transferring licensure from another state, in order to comply with the Welcome Home Act.

After the Board approved the regulatory project, staff identified additional language in the new law which should be addressed in regulation. Current regulation for issuance of a pharmacy technician certificate through license transfer, mandates successful completion of a Board-approved pharmacy technician certification examination. Act 253 list several requirements for an applicant to qualify for license transfer. Among the requirements include the following language - "the other state required the applicant to pass an examination, or to meet education, training, or experience standards."

If all requirements of the Act are met and the pharmacy technician applicant by transfer from another state was not required to pass an examination, but instead, was required to meet education, training, or experience standards for licensure, the Board is required to issue the credential.

Recognizing the “Welcome Home Act” supersedes regulation, the committee developed and approved draft #2 for consideration. Dr. Cloud then moved,

Resolved, to approve Regulatory Project 2025-03 Pharmacy Technician Certificate Qualifications - Draft #2, and further, to authorize the Executive Director to promulgate the proposed rule changes, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions. The motion was adopted after a unanimous vote in the affirmative.

- Regulatory Proposal 2025-B ~ Nonresident Pharmacy (Draft #1)

Dr. Cloud stated that during the November 2024 Board meeting, members approved a proposal to change the experience requirement to qualify for a pharmacist-in-charge privilege in Chapter 11, from two years of active practice to one year. This proposal makes the same change in Chapter 23, Nonresident Pharmacy. In addition, Board staff reviewed Chapter 23 and recommended a deletion of Section 2301(A) due to a more stringent regulation found in the same chapter.

After reviewing the proposal, the committee voted to recommend your approval. The committee developed and approved draft #1. Dr. Cloud then moved,

Resolved, to approve Regulatory Proposal 2025-B ~ Nonresident Pharmacy - Draft #1, and further, to authorize the Executive Director to promulgate the proposed rule changes, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Regulatory Proposal 2025-C ~ Practitioner CDS License (Draft #1)

Dr. Cloud reminded members that Act 444 of the 2022 Regular Session of the Legislature amended the medical marijuana law to expand the authority to issue recommendations for medical marijuana to “authorized clinicians”, then defined that term to include physicians, advanced practice registered nurses with prescriptive authority, and medical psychologists.

Dr. Cloud stated that this proposal amends CDS licensing regulation to recognize "authorized clinicians". The committee reviewed the proposal and approved draft #1 for consideration. Dr. Cloud then moved,

Resolved, to approve Regulatory Proposal 2025-C ~ Practitioner CDS License - Draft #1, and further, to authorize the Executive Director to promulgate the proposed rule change, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Rule Review ~ LAC 46:LIII.101-525

Dr. Cloud advised that Act 192 of the 2024 legislative session added a requirement that "each year, each agency shall review a sufficient number of the rules adopted by the agency so that all of the rules of the agency have been reviewed within a 5-year period and shall submit a report to the appropriate legislative oversight committee. The report shall include a listing of the rules reviewed by the agency during the previous calendar year, a description of whether each such rule is necessary and consistent with law and the agency's mission, a determination whether the probable benefits of the rule outweigh the burdens and costs on persons regulated by the rule; a complete listing of rules reviewed by the agency since the beginning of the 5 year period; and the percentage of the agency's rules that have been reviewed by the agency since the beginning of the 5 year period."

The Board currently has 258 Sections of regulations. If we review 52 Sections each year, we will complete the review in 5 years.

Staff reviewed Sections 101 through 525 and found that these Sections are necessary and consistent with law and the Board's mission. It was noted that several of these regulations are necessary because they provide information which is beneficial to our credential holders. Additionally, the probable benefits of the rules do outweigh the burdens and costs on persons regulated by the rules.

The committee agreed with the staff review and voted unanimously to accept the recommendation. Dr. Cloud then moved,

Resolved, LAC 46:LIII.101-525 are necessary and consistent with law and the Board's mission. Additionally, the probable benefits of the rules do outweigh the burdens and costs on persons regulated by the Board.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Pilot Project – Remote Processing Services – Final Product Verification

Dr. Cloud shared that during the last committee meeting, CVS Health gave a presentation and submitted a request to amend the definition of “Remote Processing Services” found in Section 1139 of the Board’s rules. He directed members to the meeting material for a copy of the presentation. The requested rule amendment is to add “final product verification” to the list of services in the definition of “Remote Processing Services”. By making such a change, a pharmacist working remotely could use current technology to provide “final product verification” which would result in the release of a prepared prescription. This technology is currently being used in approximately 34 states by CVS Health.

Dr. Cloud gave a summary of the CVS Health Air Support Program and encouraged discussion. Ms. Lauren Paul with CVS Health introduced herself, highlighted benefits of the program, and outlined the limitations of regulations. Further, she expressed the willingness of CVS Health to participate in a pilot program to demonstrate the safety of the program.

Members questioned how errors are collected, verified, and reported while noting concerns in regard to the technology and accuracy in reporting. In addition, members asked for clarification on the process including production, verification, and packaging. Ms. Paul shared the process in detail and addressed individual questions regarding such.

Further, members requested details regarding the need for less or additional pharmacist staffing and the division of responsibility within and between the pharmacies. Details were offered by CVS Health outlining the workflow.

Measurable metrics reflecting the benefit to patients and patient satisfaction was requested by members. Ms. Paul reiterated that a pilot program would allow for the collection of this data. She expressed the willingness of CVS Health to share data regarding the pilot program with the Board. Members noted that they would also appreciate feedback from the Board’s Compliance Officers during a pilot program.

Mr. McKay reminded members that data will be reviewed by the committee throughout the course of the pilot program and regulations will be drafted based on the data collected.

Dr. Cloud then moved,

Resolved, to authorize a pilot project giving CVS Health authority to operate CVS Health Air Support utilizing their remote “final product verification” feature within a specified pharmacy district in Louisiana for a period of one year from the date of implementation, while the Regulation Revision Committee reviews the current rules for off-site services and develops a regulatory proposal for the Board’s consideration.

CVS Health shall provide a single quarterly report to the Board, which identifies for each location participating in the pilot project: (1) the total number of prescriptions dispensed, compared to (2) the total number of prescriptions approved by remote “final product verification”, compared to (3) the total number of remote “final product verifications” rejected, including the reason for rejection. Additionally, CVS Health shall report any dispensing errors which occur pursuant to remote final product verification.

There were additional member questions and discussion with no public comments. A roll call vote in regard to the motion was conducted, with a vote of “yes” being in favor of the motion and a vote of “no” being against the motion, as follows:

Dr. J. Robert Cloud - Yes
Dr. David G. Collins - Yes
Mr. David A. Darce - No
Ms. Jacqueline L. Hall - Yes
Mr. Richard M. Indovina, Jr. - Yes
Mr. W. Charles Jones - No
Mr. Kevin LaGrange - Yes
Mr. Richard Mannino - No
Ms. Chris B. Melancon - Yes
Mr. J. Troy Menard - Yes
Mr. Anthony G. Mercante - Yes
Mr. Robert A. “Butch” Ray - No
Mr. Don L. Resweber - Yes
Mr. Richard A. “Andy” Soileau - Yes
Dr. Raymond J. Strong - Yes

The motion was adopted with a majority vote in the affirmative.

Dr. Cloud concluded his report by recognizing the other members of the committee – Mr. Darce, Ms. Hall, Mr. Indovina, Ms. Melancon, Mr. Menard, and Mr. Soileau.

At this point, Mr. McKay declared a recess. It was noted the members recessed at 10:30 a.m. and reconvened at 10:56 a.m.

I. Executive Committee

Mr. McKay reported the committee had met the previous day to consider the items on their posted agenda. Mr. McKay indicated Ms. Hall was prepared to offer motions on behalf of the committee and reminded the members that copies of these documents could be found in the Board member meeting material.

- **Proposed Revision to PPM.II.B.1.h ~ Telephone Procedures**

Mr. McKay explained that this proposed policy revision is the result of an upgrade to the Board's office telephone system and after reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.B.1.h ~ Telephone Procedures.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- **Proposed Revision to PPM.II.B.3.b ~ Employment**

Mr. McKay explained that this proposed policy revision updates the Board's employment policy in regard to resources new employees are responsible for familiarizing themselves with, updated language in regard to temporary appointments, and updated the role for conducting exit interviews. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.B.3.b ~ Employment.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- **Proposed Revision to PPM.II.B.3.f ~ Leave Establishment and Records**

Mr. McKay explained that this proposed policy revision removes the definition of "Restricted" and replaces it with the definition of "When Actually Employed (WAE)" to mirror State Civil Service definitions. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.B.3.f ~ Leave Establishment and Records.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to PPM.II.B.4.a ~ Employment Benefits

Mr. McKay explained that this proposed policy revision updates the reference to the enrollment period under health insurance and removed reference to the pre-existing condition clause for dependents; added reference to the dental and vision insurance options; added reference to the Pelican State Credit Union; and updated contact information for the START Savings Program. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.B.4.a ~ Employment Benefits.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to PPM.II.B.4.e ~ Annual and Sick Leave

Mr. McKay explained that this proposed policy revision replaces the definition of "Sick Leave" to concur with State Civil Service and adds the definition of "Immediate Family Member". After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.B.4.e ~ Annual and Sick Leave.

There was one member question and no public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to PPM.II.C.5.a ~ Property

Mr. McKay explained that this proposed policy revision removes the reference to R.S. 34:305.E. which has been repealed; and updated the URL to Louisiana Administrative Code – Title 34. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.C.5.a ~ Property.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to PPM.II.D.1.a ~ Computers

Mr. McKay explained that this proposed policy revision replaces the reference to Office Manager with Office of Technology Services for reporting computer problems and added that office-wide issues shall be reported to the Office Manager. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.D.1.a ~ Computers.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to PPM.II.D.2.a ~ Record Retention Schedule, Pages 5 and 7 of 8.

Mr. McKay explained that during the Board's August 2024 meeting, members approved a proposed revision to this policy. After submitting the policy for approval to the Secretary of State, they responded with suggested changes. Using the suggested language, staff prepared this draft. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.II.D.2.a ~ Record Retention Schedule, Pages 5 and 7 of 8; and further, to authorize the President to approve acceptable amendments as may become necessary in obtaining Secretary of State approval.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to PPM.IV.B.2 ~ Service Reviews

Mr. McKay explained that as directed by the Board, on November 1, 2024 the Compliance Division began using the new NABP Blueprint inspection forms for the revised standards of USP Chapters <795>, <797>, <800>, and <825>. The compliance team has reported that using the new forms has added a significant amount of time to an already lengthy inspection.

After studying the intervals between service reviews for the various types of inspections performed by the compliance team, a recommendation was developed to extend the interval between inspections from 24 to 36 months for CDS licenses issued to LDH facilities, laboratories, animal euthanasia practitioners, and researchers. By extending these intervals, the compliance team will be able to focus their time and attention on inspections of pharmacies which pose the greatest potential risk to public health and safety: permits involved in sterile compounding, hazardous drug handling, and nuclear pharmacy. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to PPM.IV.B.2 ~ Service Reviews.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Proposed Revision to LPM.I.Q ~ Transitional Duty Return to Work Plan
Mr. McKay explained that this proposed policy revision replaces prior policy with new template language provided by the Office of Risk Management – Insurance Information Notice 2025-3, to integrate the transitional return to work process into the ADA accommodation process. After reviewing the proposal, the committee voted unanimously to recommend approval. Ms. Hall then moved,

Resolved, to approve the proposed revision to LPM.I.Q ~ Transitional Duty Return to Work Plan.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- Exceptions Report
Mr. McKay reported Board policy permits the Board President to review and respond to requests for exceptions to laws, rules, and policies in the interim between meetings of the Board. Board Policy also permits the Executive Director, with concurrence of the Board President, to issue Special Work Permits and approve dual PIC privileges with notice to the Board at its next meeting. The committee reviewed the current “*Exceptions Report*” posted in the Board member reading room and the report is now presented to the full Board as required in policy. It does not require any action from the Board. There were no member questions or comments.

Mr. McKay then closed his report by expressing his appreciation to the other committee members - Ms. Hall, Mr. Resweber, Dr. Cloud, and Mr. Indovina.

11. Staff Reports

A. Report of General Counsel

Mr. McKay called upon Mr. Finalet for his report. Mr. Finalet presented the following proposed consent agreements to the members for their consideration.

Jasmin Selene Dangerfield (CPT.017867): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For her failure to report an adverse action as part of her pharmacy technician application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

MixMyRx Ventures, LLC, dba MixMyRx (Orlando, FL) (PHY.008616): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to report a March 2024 disciplinary action by the North Carolina Board of Pharmacy as part of its application for the renewal of its Louisiana pharmacy permit for 2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$5,000 plus administrative costs.

D'Shay Nicole Watson (CPT.016726): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For an alleged diversion of controlled substances, the Board revoked her credential; and further, prohibited her from applying or reapplying to practice or assist in the practice of pharmacy.

Pankajkumar Damodar Patel (PST.022312): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For his failure to report a December 2022 board order issued by the Kansas Board of Pharmacy as part of his 2025 reinstatement application for his Louisiana pharmacist license, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

Partners Pharmacy of Texas, LLC, dba Advanced Pharmacy (Stafford, TX) (PHY.007430): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to report a February 2024 disciplinary action by the Texas State Board of Pharmacy as part of its application for the renewal of its Louisiana pharmacy permit for 2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$5,000 plus administrative costs.

Hill Derm Pharmacy, Inc, dba Hill Derm Pharmacy (Sanford, FL) (PHY.008069): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to report a September 2024 disciplinary action by the Kansas Board of Pharmacy as part of its application for the renewal of its Louisiana pharmacy permit for 2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$5,000 plus administrative costs.

Corey Allen Sorrel (PST.016005): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For his failure to report a July 2024 board order issued by the Mississippi Board of Pharmacy as part of his 2025 renewal application for his Louisiana pharmacist license, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

Evan Keylon Cleaver (PST.024704): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For his failure to report a July 2024 board order issued by the Kansas Board of Pharmacy as part of his 2025 renewal application for his Louisiana pharmacist license, despite

specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

Hamilton Pharmacy and Medical Company, Inc, dba Alexander's Twin Pharmacy (Hamilton, NJ) (PHY.008475): Ms. Hall moved to accept the proposed consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. For its failure to report a March 2024 disciplinary action by the New Jersey Board of Pharmacy as part of its application for the renewal of its Louisiana pharmacy permit for 2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$5,000 plus administrative costs.

Mr. Finalet then indicated completion of his report.

B. Report of the Executive Director

Mr. McKay called upon Mr. Fontenot for his report. Mr. Fontenot directed members to the quarterly report of the Louisiana Prescription Monitoring Program (PMP) found in their meeting material, there were no member comments or questions.

Mr. Fontenot then directed the members to the requests from 15 pharmacies seeking a waiver from the duty to report zero prescription transaction reports to the PMP. Ms. Hall then moved,

Resolved, to authorize the issuance of full PMP reporting waivers to the following permits once they have executed the standard consent agreement for that purpose:

Permit No.	Permit Name
PHY.008811-IR	Align Pharmacy
PHY.008930-NR	Almac Clinical Services, LLC
PHY.008891-NR	ASAP Pharmacy
PHY.008923-NR	Brigent
PHY.008789-NR	Cure Stat Rx
PHY.008883-NR	Dania Rexall Pharmacy & Medical Supply, Inc.
PHY.008909-NR	Drugco Health
PHY.008914-HOS	Glenwood Regional Medical Center Pharmacy
PHY.008893-NR	Go MD Pharmacy, LLC
PHY.008947-NR	Morris Apothecary
PHY.008885-NR	Newark Veterinary Pharmacy
PHY.008881-NR	Nutrishare, LLC
PHY.008888-NRN	RLS (USA)
PHY.008877-NR	Spectrum Solutions Rx
PHY.008922-NR	Vetsource Home Delivery

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Mr. Fontenot then advised the members that he included both NAPLEX and MPJE passing rates for 2022-2024 graduates in the meeting material. Members noted the change in the pass rates in correlation with Covid-19 closures.

Mr. Fontenot then indicated completion of his report.

12. New Agenda Items Added During Meeting

There were no new agenda items added during the meeting.

13. Announcements

Mr. McKay directed the members to sign wall certificates.

14. Adjourn

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board and without objection, Mr. McKay adjourned the meeting at 11:20 a.m.

Minutes prepared by Joe Fontenot and then approved as presented during the subsequent meeting on May 7, 2025.

Richard M. Indovina, Jr.
Secretary